LetterLetter
Open Access

Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma

Gaofeng Zheng, Ruyi Xu, Heng Mei, Xiaoyan Han, Donghua He, Yanling Weng, Cheng Wen, Zhuoxiao Cao and Zhen Cai
Cancer Biology & Medicine October 2025, 20240581; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0581

References

  1. 1.↵
    2. Malard F,
    3. Neri P,
    4. Bahlis NJ,
    5. Terpos E,
    6. Moukalled N,
    7. Hungria VTM, et al.
    Multiple myeloma. Nat Rev Dis Primers. 2024; 10: 45.
    OpenUrlPubMed
  2. 2.↵
    2. Minakata D,
    3. Fujiwara SI,
    4. Yokoyama D,
    5. Noguchi A,
    6. Aoe S,
    7. Oyama T, et al.
    Relapsed and refractory multiple myeloma: a systematic review and network meta-analysis of the efficacy of novel therapies. Br J Haematol. 2023; 200: 694–703.
    OpenUrlPubMed
  3. 3.↵
    2. Parikh RH,
    3. Lonial S.
    Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA Cancer J Clin. 2023; 73: 275–85.
    OpenUrlPubMed
  4. 4.↵
    2. Novak AJ,
    3. Darce JR,
    4. Arendt BK,
    5. Harder B,
    6. Henderson K,
    7. Kindsvogel W, et al.
    Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004; 103: 689–94.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Berdeja JG,
    3. Madduri D,
    4. Usmani SZ,
    5. Jakubowiak A,
    6. Agha M,
    7. Cohen AD, et al.
    Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398: 314–24.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Zhao WH,
    3. Liu J,
    4. Wang BY,
    5. Chen YX,
    6. Cao XM,
    7. Yang Y, et al.
    A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018; 11: 141.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Han L,
    3. Zhang JS,
    4. Zhou J,
    5. Zhou KS,
    6. Xu BL,
    7. Li LL, et al.
    Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma. Leukemia. 2021; 35: 3002–6.
    OpenUrlPubMed
  8. 8.↵
    2. Bao C,
    3. Gao Q,
    4. Li LL,
    5. Han L,
    6. Zhang B,
    7. Ding Y, et al.
    The application of nanobody in CAR-T therapy. Biomolecules. 2021; 11: 238.
    OpenUrlPubMed
  9. 9.↵
    2. Watanabe N,
    3. Mo F,
    4. McKenna MK.
    Impact of manufacturing procedures on CAR T cell functionality. Front Immunol. 2022; 13: 876339.
  10. 10.↵
    2. Khan AN,
    3. Chowdhury A,
    4. Karulkar A,
    5. Jaiswal AK,
    6. Banik A,
    7. Asija S, et al.
    Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation. Front Immunol. 2022; 13: 886546.
  11. 11.↵
    2. Neelapu SS,
    3. Tummala S,
    4. Kebriaei P,
    5. Wierda W,
    6. Gutierrez C,
    7. Locke FL, et al.
    Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol. 2018; 15: 47–62.
    OpenUrlCrossRefPubMed
  12. 12.↵
    2. Raje N,
    3. Berdeja J,
    4. Lin Y,
    5. Siegel D,
    6. Jagannath S,
    7. Madduri D, et al.
    Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019; 380: 1726–37.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section